ProCE Banner Activity

DISCOVER: More Favorable Renal and Bone Outcomes With FTC/TAF vs FTC/TDF for HIV PrEP Through 96 Wks

Slideset Download
Conference Coverage
Longer-term follow-up demonstrates continued noninferior efficacy and more favorable bone and renal safety profile of FTC/TAF vs FTC/TDF for HIV prevention in MSM and transgender women.

Released: March 15, 2020

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

This activity is supported by educational grants from

Gilead

Merck & Co., Inc.

ViiV Healthcare